Zacks Investment Research upgraded shares of Recordati (OTCMKTS:RCDTF) from a hold rating to a buy rating in a report published on Friday. The firm currently has $51.00 target price on the stock.
According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “
Shares of Recordati (OTCMKTS:RCDTF) opened at $42.00 on Friday. Recordati has a twelve month low of $31.70 and a twelve month high of $42.00. The stock has a market capitalization of $9,933.44, a price-to-earnings ratio of 34.67, a P/E/G ratio of 2.96 and a beta of -2.86.
WARNING: “Recordati (RCDTF) Rating Increased to Buy at Zacks Investment Research” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://transcriptdaily.com/2018/01/22/recordati-rcdtf-rating-increased-to-buy-at-zacks-investment-research.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with MarketBeat.com's FREE daily email newsletter.